Resistance To Taxanes

Resistance to two taxanes, paclitaxel and docetaxel, is frequently observed in cancer patients and limits successful therapy

Lee M. Greenberger

2007

Scholarcy highlights

  • Resistance to two taxanes, paclitaxel and docetaxel, is frequently observed in cancer patients and limits successful therapy
  • Resistance to paclitaxel and docetaxel are mediated by alterations in tubulin, proteins that interact with microtubules, energy-dependent efflux pumps, apoptotic proteins, and signal transduction pathways
  • Strategies to overcome or circumvent resistance to paclitaxel or docetaxel include inhibition of efflux pumps, the use of novel taxanes or other chemically distinct classes of polymerizing agents that do not interact with drug efflux pumps, and regulation of apoptotic or signal transduction pathways that would restore sensitivity to taxanes
  • Understanding the basis of resistance at the clinical level is likely to be difficult and complex, but holds the promise of providing a therapeutic opportunity specific to taxane-resistant cancer cells

Need more features? Save interactive summary cards to your Scholarcy Library.